This Practice Review is intended to help doctors reflect on spirometry referrals and their prescribing of asthma medicines for children with asthma. It was developed in collaboration with GPs and has been sent to approximately 30,000 prescribers nationally, including all GPs.
The information on this page may help GPs interpret their individual Practice Review data.
COVID-19 updates and asthma
NPS MedicineWise recognises this is a very challenging time for GPs, patients and carers. Australian guidelines recommend spirometry to support an asthma diagnosis for children aged 6 years and over. During the current pandemic, ensure appropriate infection control procedures are in place if conducting spirometry, or refer to a respiratory laboratory service if available and practical.
If regular preventer treatment is required, guidelines recommend prescribing low-dose ICS (or montelukast) as the initial preventer for children aged 1–11. Most patients will be able to achieve good asthma control at this step.
Assess response to preventer treatment after 4–6 weeks and adjust treatment depending on the child’s age.
Step up treatment for children whose asthma remains poorly controlled despite good adherence and correct inhaler technique.
Check adherence and inhaler technique at each visit.
I would like to know more
Find out more about our national program:Paediatric asthma: breathing new life into diagnosis and management
and access a range of clinical tools and patient resources as well as CPD activities